Search results for: 'markets research'

The growth trajectory of the global life sciences industry has benefited from a combination of novel technologies such as CRISPR-Cas9, microbiome and single-cell, relaxation of entry barriers in markets like China, and better-defined regulatory frameworks around next-generation therapies and companion diagnostics. A common denominator of growth a...

08 Oct 2021  |  North America  |  Market Research

Global Tissue Diagnostics (TDx) Growth Opportunities

Companion Diagnostics (CDx)-specific Advanced Staining and Anatomical Pathology Laboratory Information Systems (APLIS) to Drive Ma

Infographics

×

This research service provides an overview of the global TDx market and a 4-year forecast of it from 2021 to 2025. The market will reach $8,848.6 million in 2025, growing at a compound annual growth rate (CAGR) of 8.9% from 2020 to 2025. The advanced staining and anatomical pathology laboratory information management systems (APLIS) segments will g...

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules and the rate of return shrinking from 16Percentage in 2011 to almost 11Percentage in 2018. Frost & Sullivan research indicates that traditional solutions that have focused primarily on data from limited sources and rule-based computational techniqu...

Readers of one of Frost & Sullivan’s media partners were invited to participate in an online survey in September 2019 that centered around the state of their laboratories in 2019 and their expectations for 2020. Frost & Sullivan has conducted similar studies among the same targeted respondents since 2012. Where applicable, the study presents year-o...

04 Sep 2018  |  North America  |  Market Research

Digital Transformation in the Pharmaceuticals Industry—Companies-to-Action, 2018

Value-based Care, Patient Data Digitization, and Collaborative Technology Deployment Offer Investment Opportunities

Infographics

×

Key Issues Addressed

The pharmaceutical industry today is in a state of flux as it tries to maintain a delicate balance between the need for novel blockbuster drugs and the need for improved operational efficiencies in an increasingly competitive market space. As healthcare is becoming increasingly democratized, patients are emerging as key decision makers—digitally en...

Clinical genomics regained significance during the pandemic with the development of the mRNA COVID-19 vaccine, and several non-invasive at-home test kits; an unprecedented feat in recent times. Genomics will take center stage, as large genome sequencing and research will continuously create data for new therapeutics. Artificial Intelligence (AI) an...

Readers of one of Frost & Sullivan’s media partners were invited to participate in an online survey in September 2020 that centered on the state of their laboratories in 2020 and their expectations for 2021. Frost & Sullivan has conducted similar studies among the same targeted respondents since 2012. Where applicable, the study presents year-ove...

An increasing focus on biologics, genomics, and multi-omics; the adoption of digital technologies; and a shift to patient-centric models are transforming the life sciences industry. At the same time, the emergence of value-based models, R&D activities to treat complex diseases, and healthcare consumerism provide an impetus to precision medicine. Wi...

Pharmaceutical drug discovery and development processes suffer from declining success rates and a stagnant pipeline. Artificial Intelligence (AI) supported by Big Data could be a key element that can provide an effectual solution. There has been a rapid growth in the data generated within the life sciences and pharmaceutical industries. This stems ...